Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by…
Read MoreScience Translational Medicine, Berrien-Elliot et al, February 2022
Read More
Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.
Read MoreClin Cancer Res, Marin et al, June 2021
Read More
Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, SENIOR EDITOR MAY 17, 2021 | 2:08 PM…
Read MoreBiotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the companyST. LOUIS, MO, and SAN…
Read More
Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.
Read More
BioWorld, David Ho, March 2021.
Read MoreST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced…
Read MoreCopyright © 2022 Wugen. All Rights Reserved.
a COGNEO design
